Assessing Treatment Outcomes of Patients Undergoing Enfortumab Vedotin Dose Reduction in Metastatic Bladder Cancer - PubMed
5 hours ago
- #Dose Reduction
- #Enfortumab Vedotin
- #Bladder Cancer
- EV dose reduction is assessed for its impact on treatment duration, TRAEs, and survival in metastatic bladder cancer.
- Three dosing groups were compared: standard dose, on-treatment reduction, and upfront reduction, with analyses adjusting for factors like age and ECOG status.
- On-treatment dose reduction was associated with more cutaneous AEs and neuropathy but improved PFS in landmark analyses, and time-varying analyses showed better PFS and OS with reduced doses.
- Conclusions indicate that dose reduction maintains efficacy while reducing AEs, supporting prospective evaluation.